Validation of a Rapid Molecular Assessment Platform and Cytokine Score for Integration with Ex Vivo Lung Perfusion (EVLP) Assessment

We have performed a retrospective validation and initial prospective test of a rapid perfusate diagnostic platform that measures lung injury biomarkers in less than 45 minutes-well within the typical 4-6 hour EVLP assessment and decision-making time frame. Data from our EVLP cytokine score performance on the rapid diagnostic platform will serve as a foundation for future integration into the clinical EVLP operating room. By enabling molecular testing during EVLP, these results represent another step towards better-assisting clinicians to more precisely select suitable lungs for transplantation.